Humacyte FY2024 EPS Forecast Decreased by Cantor Fitzgerald

Humacyte, Inc. (NASDAQ:HUMA) – Equities researchers at Cantor Fitzgerald reduced their FY2024 earnings estimates for Humacyte in a research report issued on Monday, November 11th. Cantor Fitzgerald analyst K. Kluska now expects that the company will post earnings per share of ($1.41) for the year, down from their prior estimate of ($1.23). Cantor Fitzgerald currently has a “Overweight” rating and a $13.00 price objective on the stock. The consensus estimate for Humacyte’s current full-year earnings is ($1.22) per share.

HUMA has been the subject of several other research reports. Piper Sandler set a $6.00 price target on shares of Humacyte and gave the company a “neutral” rating in a research report on Friday, October 18th. BTIG Research restated a “buy” rating and issued a $10.00 price target on shares of Humacyte in a research note on Friday, October 18th. TD Cowen reaffirmed a “buy” rating and set a $10.00 price target on shares of Humacyte in a report on Friday, October 18th. Benchmark reiterated a “buy” rating and issued a $15.00 price objective on shares of Humacyte in a report on Thursday, October 10th. Finally, HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Humacyte in a research note on Wednesday. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $11.00.

Humacyte Price Performance

NASDAQ:HUMA opened at $4.84 on Thursday. The firm has a 50-day simple moving average of $5.43 and a two-hundred day simple moving average of $6.16. The firm has a market cap of $577.06 million, a P/E ratio of -3.61 and a beta of 1.47. Humacyte has a fifty-two week low of $2.35 and a fifty-two week high of $9.97. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.41 and a current ratio of 1.10.

Humacyte (NASDAQ:HUMA) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04).

Institutional Trading of Humacyte

Several institutional investors and hedge funds have recently modified their holdings of the company. State Street Corp raised its holdings in Humacyte by 66.1% during the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock valued at $25,917,000 after acquiring an additional 1,895,529 shares during the period. Millennium Management LLC raised its stake in Humacyte by 504.3% during the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock valued at $7,677,000 after purchasing an additional 1,334,641 shares during the period. Vanguard Group Inc. raised its stake in Humacyte by 28.7% during the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock valued at $12,501,000 after purchasing an additional 896,415 shares during the period. Renaissance Technologies LLC lifted its holdings in Humacyte by 693.0% in the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after purchasing an additional 524,600 shares in the last quarter. Finally, Marshall Wace LLP boosted its stake in Humacyte by 3,301.5% in the 2nd quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock worth $2,226,000 after purchasing an additional 450,031 shares during the period. 44.71% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, Director Kathleen Sebelius sold 5,182 shares of the company’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $5.40, for a total value of $27,982.80. Following the completion of the sale, the director now directly owns 40,276 shares in the company, valued at $217,490.40. This represents a 11.40 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Brady W. Dougan sold 252,676 shares of the business’s stock in a transaction dated Tuesday, August 27th. The shares were sold at an average price of $6.71, for a total value of $1,695,455.96. Following the sale, the director now directly owns 4,306,464 shares of the company’s stock, valued at $28,896,373.44. This represents a 5.54 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 1,084,153 shares of company stock valued at $6,869,996. Insiders own 11.20% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.